Status: Not yet recruiting
RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Disitamab Vedotin（RC48）combined with EGFR or HER2 TKIs in locally advanced or metastatic NSCLC Patients with HER2 Alterations.
Participants needed: 108
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesUpdated: Dec 29, 2023
Eligibility criteria
Age: 18 (inclusive) or above, regardless of gender. [+7]
Central nervous system metastasis or meningeal metastasis with clinical symptoms... [+6]